Online inquiry

IVTScrip™ mRNA-Anti-IL20, NN-8226(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ12478MR)

This product GTTS-WQ12478MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets IL20 gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001385165.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 50604
UniProt ID Q9NYY1
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL20, NN-8226(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ12478MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11322MR IVTScrip™ mRNA-Anti-F, MEDI-524(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MEDI-524
GTTS-WQ7839MR IVTScrip™ mRNA-Anti-RTN4, GSK-1223249(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA GSK-1223249
GTTS-WQ378MR IVTScrip™ mRNA-Anti-TYRP1, 20D7S(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA 20D7S
GTTS-WQ4308MR IVTScrip™ mRNA-Anti-C1S, BIVV009(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BIVV009
GTTS-WQ13120MR IVTScrip™ mRNA-Anti-APP, PF-04360365(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA PF-04360365
GTTS-WQ2466MR IVTScrip™ mRNA-Anti-ITGA4&ITGB7, AMG 181(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA AMG 181
GTTS-WQ14398MR IVTScrip™ mRNA-Anti-IFNA1, RhuMAB IFNalpha(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA RhuMAB IFNalpha
GTTS-WQ14702MR IVTScrip™ mRNA-Anti-SELP, SEG101(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA SEG101
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW